Atsushi Natsume Selected Research

Antigens

7/2012	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A24/A02 allele.
12/2010	Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
6/2010	Epigenetic aberrations and therapeutic implications in gliomas.
3/2009	Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
7/2008	Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.
6/2008	The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsushi Natsume Research Topics

Disease

64	Neoplasms (Cancer) 08/2023 - 09/2005
61	Glioma (Gliomas) 01/2023 - 09/2005
34	Glioblastoma (Glioblastoma Multiforme) 09/2023 - 07/2007
19	Brain Neoplasms (Brain Tumor) 08/2023 - 04/2006
8	Carcinogenesis 08/2023 - 10/2009
7	Meningioma (Meningiomas) 11/2021 - 04/2005
5	Spinal Cord Injuries (Spinal Cord Injury) 02/2021 - 10/2007
3	Lymphoma (Lymphomas) 01/2023 - 11/2011
3	Moyamoya Disease (Moya-Moya Disease) 08/2021 - 01/2020
3	Gliosis 12/2014 - 01/2009
3	Testicular Neoplasms (Testicular Cancer) 06/2010 - 06/2008
2	Microsatellite Instability 08/2022 - 05/2020
2	Thrombosis (Thrombus) 08/2021 - 01/2021
2	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2021 - 10/2020
2	Germinoma 01/2021 - 01/2021
2	Ependymoma 01/2021 - 03/2009
2	Necrosis 06/2020 - 12/2018
2	Neuroepithelial Neoplasms (Gliomatosis Cerebri) 04/2020 - 05/2019
2	Neoplasm Metastasis (Metastasis) 12/2018 - 05/2006
2	Inflammation (Inflammations) 12/2018 - 05/2018
2	Melanoma (Melanoma, Malignant) 05/2018 - 08/2003
2	Brain Ischemia (Cerebral Ischemia) 11/2017 - 11/2010
2	Leukemia 01/2017 - 03/2013
2	Infections 01/2015 - 07/2014
2	Cognitive Dysfunction 11/2010 - 08/2007
2	Ischemic Stroke 11/2010 - 08/2007
2	Brain Stem Neoplasms (Brain Stem Tumor) 07/2009 - 03/2009
2	Astrocytoma (Pilocytic Astrocytoma) 07/2008 - 08/2007

Drug/Important Bio-Agent (IBA)

20	Temozolomide (Temodar)FDA LinkGeneric 05/2020 - 09/2005
11	Proteins (Proteins, Gene)FDA Link 08/2019 - 01/2004
10	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2023 - 03/2013
10	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 08/2007
8	Interferon-betaIBA 05/2020 - 08/2003
7	InterferonsIBA 06/2020 - 07/2006
6	Histones (Histone)IBA 09/2023 - 03/2009
6	Biomarkers (Surrogate Marker)IBA 08/2023 - 06/2010
6	epidermal growth factor receptor VIIIIBA 06/2020 - 12/2010
6	MethyltransferasesIBA 05/2020 - 04/2008
6	Alkylating AgentsIBA 10/2013 - 09/2005
6	AntigensIBA 07/2012 - 06/2008
5	CytokinesIBA 08/2021 - 04/2005
5	ErbB Receptors (EGF Receptor)IBA 06/2020 - 04/2006
5	Chimeric Antigen ReceptorsIBA 06/2020 - 01/2013
5	Peptides (Polypeptides)IBA 01/2019 - 12/2003
5	Liposomes (Liposome)IBA 01/2014 - 08/2003
4	ranimustineIBA 10/2013 - 07/2006
3	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 09/2021 - 03/2012
3	Polycomb Repressive Complex 2IBA 10/2019 - 07/2009
3	GuanineIBA 01/2017 - 04/2012
3	O(6)-Methylguanine-DNA MethyltransferaseIBA 01/2014 - 08/2007
3	Antineoplastic Agents (Antineoplastics)IBA 10/2013 - 09/2005
2	Transcription Factors (Transcription Factor)IBA 09/2023 - 02/2021
2	ChromatinIBA 01/2023 - 07/2013
2	Methotrexate (Mexate)FDA LinkGeneric 01/2023 - 01/2017
2	Glycoproteins (Glycoprotein)IBA 09/2022 - 05/2018
2	ParaffinIBA 08/2022 - 07/2014
2	Formaldehyde (Formol)FDA Link 08/2022 - 07/2014
2	Immune Checkpoint InhibitorsIBA 08/2022 - 12/2016
2	poliferprosan 20 drug combination carmustine (Gliadel)FDA Link 01/2022 - 01/2015
2	RNA (Ribonucleic Acid)IBA 11/2021 - 01/2018
2	GangliosidesIBA 09/2021 - 06/2015
2	A-Form DNA (A-DNA)IBA 09/2021 - 01/2014
2	GD3 ganglioside (GD(3))IBA 08/2021 - 06/2015
2	MicroRNAs (MicroRNA)IBA 04/2021 - 12/2009
2	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 01/2021
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 04/2020 - 05/2019
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2020 - 04/2006
2	AntibodiesIBA 05/2018 - 12/2016
2	Phosphotransferases (Kinase)IBA 01/2018 - 06/2015
2	Oxygen (Dioxygen)IBA 11/2017 - 03/2013
2	Carboplatin (JM8)FDA LinkGeneric 01/2017 - 11/2011
2	Ifosfamide FDA LinkGeneric 01/2017 - 11/2011
2	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 11/2011
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2017 - 11/2011
2	Glutamic Acid (Glutamate)FDA Link 12/2014 - 06/2014
2	NimustineIBA 10/2013 - 07/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2013 - 04/2005
2	Small Interfering RNA (siRNA)IBA 06/2013 - 07/2007
2	Green Fluorescent ProteinsIBA 06/2013 - 03/2012
2	Free Radical ScavengersIBA 11/2010 - 08/2007
2	EdaravoneIBA 11/2010 - 08/2007
2	Decitabine FDA Link 03/2009 - 06/2008
1	Cell-Free Nucleic AcidsIBA 08/2023
1	Vincristine (Oncovin)FDA LinkGeneric 01/2023
1	Procarbazine (Matulane)FDA Link 01/2023
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2023
1	alpha-hydroxyglutarateIBA 01/2023
1	Genetic Markers (Genetic Marker)IBA 01/2023
1	Rituximab (Mabthera)FDA Link 01/2023
1	MucinsIBA 09/2022
1	Carmustine (FIVB)FDA Link 01/2022

Therapy/Procedure

29	Therapeutics 01/2023 - 07/2007
22	Radiotherapy 01/2023 - 04/2006
17	Drug Therapy (Chemotherapy) 01/2023 - 04/2006
7	Immunotherapy 01/2020 - 06/2008
3	Precision Medicine 01/2021 - 04/2017
3	Craniotomy 10/2019 - 07/2014
2	Ligation 04/2020 - 05/2019
2	Aftercare (After-Treatment) 07/2015 - 08/2003
2	Spinal Fusion (Spondylosyndesis) 01/2014 - 01/2012